Weight of evidence Mode of action Adverse outcome pathway a b s t r a c t A Weight-of-evidence (WoE) evaluation should be applied in assessing all the available data for the identification of endocrine disrupting (ED) properties of chemicals. The European Commission draft acts specifying criteria under the biocidal products and plant protection products regulations require that WoE is implemented for the assessment of such products. However, only some general considerations and principles of how a WoE should be conducted are provided. This paper reviews WoE approaches to distil key recommendations specifically for the evaluation of potential ED properties of chemicals. In a manner, which is consistent with existing, published WoE frameworks, the WoE evaluation of ED properties can be divided into four phases: 1) Definition of causal questions and data gathering and selection, 2) Review of individual studies, 3) Data integration and evaluation, and 4) Drawing conclusions based on inferences. Recommendations are made on how to conduct each phase robustly and transparently to help guide the WoE evaluation of potential endocrine disrupting properties of chemicals within a European regulatory context.
Introduction
The European Commission adopted the WHO IPCS definition of an endocrine disruptor, which is "an exogenous substance or mixture that alters function(s) of the endocrine system and consequently causes adverse health effects in an intact organism, or its progeny, or (sub)populations" (EC, 2016; WHO IPCS, 2002) . As required by the legislation governing biocidal products (BPs) and plant protection products (PPPs), the European Commission has drawn up draft acts specifying scientific criteria for the determination of endocrine disrupting properties. According to these criteria, a substance shall only be considered as having endocrine disrupting properties if it fulfils the three elements of the definition, i.e. a) that it shows an adverse effect in an intact organism, b) it has an endocrine mode of action, i.e. it alters the function(s) of the endocrine system, and c) the adverse effect is a consequence of the endocrine mode of action.
The process of determining whether a substance fulfils this definition and the regulatory criteria for establishing potential endocrine disrupting (ED) properties involves the evaluation and integration of data from multiple types of studies (cf. in silico and in vitro screens, in vivo mechanistic assays, and in vivo apical studies) of varying relevance and reliability. The European Commission draft text for ED criteria specifies that a "weight of evidence" (WoE) evaluation should be applied in assessing all the available data (EC, 2016) ; however, the draft only provides some general considerations and principles of how a WoE should be conducted.
WoE can be defined as a framework for synthesising various lines of evidence, using interpretative methods to integrate the data. Several peer reviewed papers and regulatory guidance documents have been published which evaluate, propose or adopt either qualitative or (semi-)quantitative WoE frameworks. These employ different methods for the evaluation of mode of action for the evaluation of ED properties. ECHA and EFSA are currently drafting guidance for the implementation of hazard-based ED criteria for PPPs and BPs, which will include a WoE approach for the evaluation of available information (ECHA/EFSA, 2016). It should be noted that the draft EC criteria represent a hazard identification process and do not extend to a full hazard characterisation. Hazard characterisation entails determining the relationship between the magnitude of exposure and the severity of any adverse effects, as well as setting safe threshold values. A full discussion of hazard identification, hazard characterisation and risk assessment for potential endocrine disrupting chemicals (EDC)s is beyond the scope of this paper. Here we focus on the imminent regulatory need in Europe for an approach to data collection, evaluation and integration to facilitate the determination on endocrine disrupting properties of chemicals. Rhomberg et al. (2013) recently conducted an extensive survey of 50 WoE frameworks in a broader context, with the aim of identifying best practices in conducting WoE analyses. It was not the intention or within the scope of this review to repeat the work of Rhomberg et al., but to evaluate the suitability of a range of published approaches specifically for WoE evaluations for potential endocrine disrupting properties. The aim of this paper was to review endocrine-specific WoEs and distil key recommendations for WoE evaluations of potential endocrine disrupting properties of chemicals within a European regulatory context.
Methods
As a first step, key pieces of legislative texts, guidance documents, and opinions of scientific advisory groups and committees were reviewed and key sections extracted or summarised. This information is provided in Table S1 in the Supplementary material. Whilst the majority of these sources do not provide practical guidance on how to perform a WoE, they list general factors to be considered during such an evaluation.
Searches for WoE frameworks or substance-specific WoEs in the open scientific literature were conducted using Toxline (United States National Library of Medicine), spanning the last 20 years (1997e2017) and using the following key words: "weight of evidence" AND "endocrine". The titles and abstracts were screened for relevant publications proposing, describing, or applying WoE frameworks for EDs in general or substance-specific WoE reviews. General frameworks were also included if they pertained to the evaluation of mode of action. The shortlisted papers included a selection of different WoE methods, including examples of a) systematic reviews with specified criteria for drawing conclusions, b) semi-quantitative or quantitative methods for assigning weights and relevance to various studies, and c) causal criteria for the evaluation of mode of action.
Results and discussion
3.1. Review of general and ED specific WoE frameworks Rhomberg et al. (2013) conducted an extensive review of available WoE frameworks in a general context, i.e. not specifically for the evaluation of endocrine disrupting properties, and the reader is referred to this work for an overarching review. Four specific frameworks were reviewed for the WoE of EDs or MoA and their main points are summarised in Table 1. The WHO/IPCS MoA/species concordance (Meek et al., 2014) and Adverse Outcome Pathway (AOP; e.g. Mihaich et al. (2017) frameworks are conceptually similar approaches and are well established and accepted methods to evaluate the evidence available for biologically plausible causal relationships between the mechanism and adverse effects observed in a dataset under evaluation. Both represent the subdivision of a pathway between exposure and effect into a series of hypothesised key events at different levels of biological organisation (e.g. molecular, subcellular, cellular, tissue). The main distinction between the two approaches is that the term MoA, does not per se imply adversity of the outcome, and can be applied equally to therapeutic interventions (Meek et al., 2014) . Both MoA and AOP evaluations use modified Bradford Hill considerations (Hill, 1965) for the WoE evaluation of the evidence supporting an MoA or AOP. Borgert et al. (2014) propose a framework in which each experimental endpoint in the 11 Endocrine Disruptor Screening Program (EDSP) Tier 1 endocrine screening battery (ESB) of tests is assigned a rank weight, according to its relevance for informing the eight individual hypotheses tested by the ESB. The approach proposed by Borgert et al. (2014) is best suited to the context it was designed for, i.e. the evaluation of a full set of EDSP Tier 1 battery of tests. This is a highly standardised data set, which will not be typical for all substances being evaluated in the EU. Standard (eco) toxicology studies conducted for pesticide registrations, or other higher tier tests which fall in OECD CF Levels 4 and 5 are not included in this framework, since they are outside the scope of evaluating EDSP Tier 1 mechanistic assays. Whilst they are relevant for the determination of apical adverse effects, they are generally less useful for identifying MoAs (Borgert et al., 2014) . However, as illustrated by some published WoEs which adopt this framework (see substance specific evaluations in Section 3.2; Mihaich et al., 2017; De Peyster and Mihaich, 2014) , they can be used as Other Scientifically Relevant Information (OSRI) in the WoE to provide further support for lines of argumentation following the determination of endocrine activity in this framework.
Data integration and evaluation methods that result in categories of endocrine disrupting potential, such as possible, probable, or known endocrine disrupters are not consistent with the recommendations proposed by the European Commission. For this reason, the Systematic and Integrated Assessment (SYRINA) proposed by Vandenberg et al. (2016) was not considered appropriate for further consideration in a European regulatory context.
Review of published substance specific WoEs
Six WoE studies, covering seven substances were selected and reviewed as examples to determine how different WoE approaches have been adopted in practice. The published WoE evaluations were all conducted for data-rich substances, i.e. triclosan (Mihaich et al., 2017) , methyl tertiary-butyl-ester (MTBE; De Peyster and Mihaich, 2014), pronamide (Marty et al., 2015) , chlorpyrifos (Juberg et al., 2013 ), ethinylestradiol, vinclozolin (Hutchinson et al., 2013 and atrazine (Van der Kraak et al., 2014) . The approaches included: a) hypothesis-based WoE using ranking of the mechanistic evidence (Mihaich et al., 2017; De Peyster and Mihaich, 2014) ; b) hypothesis-based evaluations in which the data were structured and organised according to the OECD Conceptual Framework Levels (Juberg et al., 2013; Hutchinson et al., 2013) or assay/ study type (Marty et al., 2015) ; c) and quantitative scoring/weighing of the evidence (Van der Kraak et al., 2014) .
The substance-specific WoE evaluations reviewed included the four phases of WoE identified by Rhomberg et al. (2013) , although they differ in detail: Phase 1) Causal question definition and data selection; Phase 2) Review of individual studies (evaluating the studies, assessing their quality and consistency); Phase 3) Data integration and evaluation (integrating the assembled information to assess their bearing on assertions of causal processes); and Phase 4) Drawing conclusions based on inferences. The elements and features of each WoE approach are summarised below and in Table 2 . The aim of Hutchinson et al.'s (2013) paper was to illustrate how the OECD CF could be used to structure available data for two known model compounds (ethinylestradiol and vinclozolin), and therefore did not include all four phases. Phase 1: Causal question and criteria for data selection The hypothesis-based WoE evaluations articulated the problem formulation according to each of the estrogen, androgen, thyroid and steroidogenesis (EATS) pathways evaluated, i.e. the potential of a chemical to interact as agonists or antagonists of the EAT pathways or inducers or inhibitors of steroidogenesis enzymes (De Peyster and Mihaich, 2014; Juberg et al., 2013; Marty et al., 2015; Mihaich et al., 2017) . The hypothesis in van der Kraak et al.'s (2014) quantitative WoE was, "Environmentally relevant concentrations of [the substance] do not cause effect "x"", with "x" representing each apical and sub-apical endpoint evaluated.
The methods used to search the open literature were documented in three of the WoEs (Table 2 ). The selection criteria were outlined in all of the WoEs. Where the substance was subject to US EPA EDSP Tier 1 testing, then these data formed the core basis for the evaluation of endocrine activity. If the substance was a pesticide, then standard regulatory studies required for pesticide (Mihaich et al., 2017) The approach recommends the assembly and full, transparent documentation of individual lines of evidence within the conceptual framework of an Adverse Outcome Pathway (AOP). Modified Bradford Hill considerations are used to 1) test the biological plausibility that the response is acting through an endocrine mechanism, 2) determine the essentiality of upstream events to cause downstream effects, and 3) determine the strength of empirical evidence that an observed effect is caused by disruption of an upstream endocrine mechanism. Rank Order weighting of EDSP Tier 1 assays (Borgert et al., 2014) Each experimental endpoint in the 11 EDSP Tier 1 endocrine screening battery (ESB) of tests is assigned a rank weight, according to its relevance for informing the hypotheses tested by the ESB, i.e. the potential of the chemical to interact with the estrogen, androgen, thyroid and steroidogenesis (EATS) pathways. The consistency or inconsistency across Rank 1, 2 and 3 data is assessed, with greater weight given to Rank 1 data, and Rank 2 and 3 data either strengthening or tempering support. It should be noted that the focus of this framework is the evaluation of the EDSP Tier 1 results for endocrine activity, and that within this context "evidence" pertains to the potential of a substance to operate via specific MoAs; it does not pertain to or predict an ability to cause any particular type of effect, including adverse effect" (Borgert et al., 2014) . Systematic review and integrated assessment (SYRINA; Vandenberg et al., 2016) The proposal includes the following steps: 1) Formulate the problem, 2) Develop the review protocol, 3) Identify relevant evidence, 4) Evaluate evidence from individual studies, 5) Summarise and evaluate each stream of evidence, 6) Integrate evidence across all streams, 7) Draw conclusions, make recommendations, and evaluate uncertainties.
Step 5 proposes an analysis of the strength of association between exposure and adverse effects and between exposure and endocrine activity, using the descriptors high, medium, low, or absent for the strength of evidence. In
Step 6 the strength of evidence descriptors are addressed for adverse effects and endocrine activity which are integrated into a matrix in order to conclude on ED potential. The outcome of the decision matrix is a classification of a compound as either a known, probable, or possible EDC, or that the substance is not classifiable (e.g. when no data or not enough data are available).
registration were also included. For these and the industrial chemicals, the US EPA Tier 1 assays and endpoints were used to guide the selection of relevant studies in the open literature, as was professional judgement as to whether a study was likely to provide information of relevance, which focused on the assessment of the EATS pathways.
Phase 2: Review of individual studies
Three of the six evaluations used ToxRTool to assess data quality. The JRC ToxRTool 1 is an Excel-based tool, which guides the assignment of Klimisch reliability scores (Schneider et al., 2009) . The tool provides comprehensive criteria and guidance for the evaluation of reliability of studies that makes the decision process for assigning reliability scores more transparent. Two studies used Klimisch criteria, one of which used the ToxRTool recommendations to guide the assignment of Klimisch scores. The quantitative WoE evaluation used a specifically developed scoring system based on numerical scores for individual criteria to derive an overall "strength of methods" score.
In the evaluations using ToxRTool or Klimisch scores, unreliable data (Klimisch or ToxRTool score 3 studies) were excluded from the WoE analysis. The reviews differed in the level of detail provided to justify the data as unreliable, e.g. full discussion of effects observed and reason for unreliability within the main narrative or no mention of the effects observed in these studies within the main narrative, but inclusion of the reference, unreliability rating, and justification for exclusion in supplemental material. In the quantitative WoE, the unreliable data were not excluded, since the low reliability score assigned reflected the relative weight of the unreliable study during the data integration step.
Phase 3: Data integration and evaluation Semi-quantitative weighting of relevance (ranking) of mechanistic data
The Rank scores proposed by Borgert et al. (2014) were adopted in two of the evaluated reviews (Mihaich et al., 2017; De Peyster and Mihaich, 2014) . In Mihaich et al. (2017) the eight MoA tables of endpoints from Borgert et al. (2014) were used to organise the available data. In these tables, all ranked endpoints of the EDSP Tier 1 battery were listed, and the negative, positive, or absent data from the battery of tests were entered. Documentation of the data in this way provided an overview of the number and direction of responses observed, and any data gaps. This process facilitated an evaluation of the lines of evidence for a particular MoA, and helped identify the consistency of endpoints within and across studies. Available standard toxicity data from OECD Levels 4 and 5 were not tabulated or ranked, but were included, where available, in a summary of other scientifically relevant information in the discussion of the WoE, to lend further supporting weight to specific lines of evidence.
De Peyster and Mihaich (2014) noted in their evaluation that "a number of endpoints were identified in the literature that appear relevant for inclusion in an assessment of endocrine activity but are not in the US EDSP screens, and thus assignment of relevance ranks has not previously been proposed". Where reproductive, developmental toxicity and carcinogenicity studies characterised the weight and histopathology of endocrine relevant organs, these were used to provide additional information for some ranked endpoints (e.g. testis weight and histopathology from rodent studies including pre-/peripubertal exposures were included in the tables as Rank 2 endpoints). In this WoE evaluation, the tables were organised by endpoints, rather than EDSP battery tests (e.g. female rodent studies: ovarian weight and ovarian histopathology, rather than pubertal female assay) to allow endpoints from other test designs to be entered. Apical effect endpoints (fertility and reproductive indices, foetal examination results, tumour incidences) from the longer-term studies falling in Levels 4 and 5 of the OECD CF were not ranked in this framework, but contributed in the discussion to the assessment of the substance being investigated to cause adverse effects, following WoE analysis of the mechanistic data.
The WoE for each endocrine pathway (EATS) was conducted taking into account the evidence for Rank 1, 2, and 3 endpoints, in accordance with the guidance published by Borgert et al. (2014) . In addition, where effects on individual endpoints within a study were noted, Mihaich et al. (2017) also compared the isolated response to the pattern of responses that would be expected with a model compound (e.g. ethinylestradiol, propylthiouracil).
In the evaluation of De Peyster and Mihaich (2014) the WoE of the ranked mechanistic data were not sufficiently consistent across the studies to support interaction with any of the endocrine pathways. However, in order to help explain the few effects on endocrine organs that were observed, an alternate MoA was proposed, with some supporting evidence. These two latter points, comparison of effects with the expected pattern of effects known for the hypothesised MoA and exploration of alternate MoAs are specific steps recommended in the WHO/IPCS MoA framework and by Rhomberg et al. (2013) .
Qualitative weight of evidence Another approach that has been adopted is to use the OECD Conceptual Framework (CF) for testing and assessment of potential endocrine disrupting chemicals to facilitate the organisation of data across multiple levels of biological complexity in a clear and transparent manner (e.g. Juberg et al., 2013; Hutchinson et al., 2013) . The OECD CF represents a pragmatic hierarchy in which the various mechanistic assays and studies are placed, with each of the CF Levels corresponding to a different level of biological complexity for mammalian and non-mammalian wildlife. The OECD CF is supported by OECD GD 150 (OECD, 2012), which provides in depth guidance on the interpretation of results from studies in the OECD CF. Marty et al. (2015) did not specifically evaluate the data within the structure of the OECD CF, but assigned qualitative weights in the following order: intact in vivo assay > in vivo systems without an intact HPG axis > in vitro systems. Whilst the OECD CF Levels were not specifically used, the level of significance assigned to the studies is consistent with the OECD CF Levels.
The OECD CF is compatible with data from the EPA EDSP. Where data from the EPA EDSP Tier 1 test battery were evaluated, these were assigned the respective levels of the OECD CF (e.g. Juberg et al., 2013) . In the process of integrating the data, these hypothesis-based evaluations addressed each endocrine pathway in turn, tabulating and evaluating the consistency of positive or negative results within assays and the coherence of all effects observed across CF levels for each pathway separately. Organisation of the data in the OECD CF allowed patterns of effects or discordant findings to be identified and discussed. Marty et al. (2015) in their assessment of pronamide included a full narrative and tabular summary of all standard toxicity studies available for the substance (studies required for pesticide registration) as well as specific investigations (e.g. thyroid MoA and Leydig cell tumour MoA studies). This included a summary of all effects observed in the studies, including systemic effects (e.g. effects on body weight gain, weight, and histopathology of liver), in addition to any effects relevant for the assessment of potential endocrine disruption (e.g. weight and histopathology of endocrine organs, reproductive and development effects). The endocrine relevant effects observed in these and the mechanistic studies were put into context with other effects observed, the liver having been identified as the primary target organ for toxicity across the available studies. In the WoE analysis, alternate MoA were discussed and evaluated, i.e. the evidence base supporting hepatic enzyme induction and subsequent clearance of steroid and thyroid hormones was presented. The consideration of alternative MoA is a recommended step in the WHO/IPCS MoA and AOP frameworks.
Another feature of Marty et al.'s (2015) evaluation was the comparison of the effects observed in the mechanistic assays with the expected pattern of effects from model compounds for each assay.
Quantitative WoE van der Kraak et al. (2014) developed and applied a quantitative WoE analysis in their evaluation of atrazine effects in fish, amphibians, and reptiles. In this approach, each study was evaluated according to several criteria for a) relevance of response to adverse outcomes and b) the strength of methods (SOM). A numerical score of 0e4 was assigned to each criterion (elaborated in detail in the methods and summarised in a table in the publication).
The scores for relevance and SOM were used only for the purposes of ranking individual studies. To visualise the scores, individual studies that reported a particular response (e.g. abnormalities in testes) were plotted on the x and y axes of a graph. The location of the points within the quadrant provided a measure of the SOM and relevance of findings to adverse effects for a particular study. Clustering of studies was considered indicative of consistency between observations in different studies, and outliers could easily be identified and addressed in the narrative discussion of the studies. For each response, the mean and 2Â standard error of the scores for strength and relevance of all studies for a response were plotted as a summary of the individual responses. Clustering on the left side of the graph indicated weak to no relevance of the responses to adverse effects. The mean scores for relevance were used to provide a simple indicator of causality, with mean scores of 3 or greater resulting in the rejection of the null hypothesis, scores of 0 resulting in acceptance of the null hypothesis and means scores >1 and < 3 indicating equivocal evidence that the null hypothesis is not rejected.
The authors suggested the use of AOPs when relevant effects on apical endpoints are observed, in order to develop an understanding of the mechanisms at lower levels of organisation. However, if no relevant apical effects are affected, an analysis of AOPs is not required. Organisation of the data within an AOP demonstrated that weak data for effects at each level of biological organisation resulted in an incomplete AOP.
The quantitative approach adopted by Van der Kraak et al. (2014) is suitable for substances, for which sufficient, suitable data are available. It should be noted that the evaluation of both relevance and SOM in this approach included criteria for exposure level in order to address the specific null hypothesis that environmentally relevant concentrations of atrazine did not cause effect "x". Whilst this method does not represent a formal risk assessment, an element of risk is built into the scores. Studies that used high concentrations were scored lower than studies that used environmentally relevant concentrations in the evaluation of SOM and a multiplier was applied for relevance of response based on whether the LOEC was above or below a certain concentration. Whilst perhaps useful for addressing the specific hypothesis of this paper, the inclusion of exposure or risk considerations is not supported by the European Commission as part of the hazard identification step for ED evaluation. However, the evaluation conducted by Van der Kraak et al. (2014) highlights the importance of considering environmentally relevant concentrations and that safe thresholds can be established, above which adverse effects will not be observed.
Phase 4: Conclusions In the majority of WoE examples reviewed, each MoA was evaluated separately, to determine whether there was consistent evidence, absence of evidence, or inconsistent evidence to support a particular hypothesis. The conclusions for each hypothesised MoA were therefore directly based on the results and discussion presented for each pathway. Rhomberg et al. (2013) make useful distinctions in defining WoE evaluations. They refer to the process of data selection, collation, and abstraction as "systematic review". This is considered as a distinct step from the process of evaluating the support the data may or may not provide for causal inferences, which they refer to as "integration and weighing of the evidence". The process as a whole is termed a WoE evaluation and is sub-divided into four phases. Based on the review of the published WoE frameworks in Section 3, some recommendations are made below on how the process could be applied to the assessment of potential endocrine disrupting properties, and which steps should be included in the four phases. The recommendations are summarised below and a flow diagram for the recommended process is presented in Fig. 1 .
Recommendations
Phase 1: Definition of causal question and data selection Causal question Depending on the question to be answered, the causal question for the evaluation of a potential ED properties can be phrased in different ways. For example, the specific evaluation of endocrine activity in the US EPA EDSP Tier 1 battery of tests will result in a causal question that focuses only on the endocrine activity and not on adverse effects. Within a European regulatory context, the problem formulation should be articulated around the WHO definition of an endocrine disrupter to encompass the adverse effect and not just endocrine activity, e.g. "Does a substance fulfil the WHO definition of an endocrine disrupter?" This can be further defined according to the EC Communication (2016) on endocrine disrupters, e.g. "Is there a reasonable evidence base for a biologically plausible causal relationship between the [endocrine mode of action] and the adverse effects seen in intact organism studies?" This can be initially limited to the E, A, T, and S pathways, and expanded as our understanding and the availability of tests increase to encompass other endocrine mechanisms.
Data collection and selection The draft criteria proposed under the Plant Protection Products and Biocides regulations state that the identification of a substance as having ED properties shall be based on all relevant data available from studies generated according to internationally agreed protocols and other scientific data by applying a systematic review methodology. The aim of systematic reviews (as delimited to the process of data selection, collation, and abstraction) is to provide clarity, transparency, rigour, and reproducibility to these steps (Weed, 2005) . A systematic search of the regulatory, open literature and other relevant data sources (e.g. ToxCast database) should be performed and documented in a transparent manner so that relevance considerations can be subsequently assessed and revised if necessary. In the interest of harmonisation, existing EFSA guidance (EFSA, 2011), which recommends how searches and identification of scientific peer-reviewed open literature studies should be conducted and reported for inclusion in plant protection products dossiers, should be used for this process. The inclusion and exclusion criteria should be clearly identified a priori and documented as part of the process. Following the conduct of the literature searches, all studies included for the review should be reported, as well as all the studies that were excluded, as a record of the searches.
Whilst the EFSA (2011) guidance on systematic review of open literature studies requires an a priori decision on and documentation of inclusion and exclusion criteria for study selection, it does not provide specific advice on how to define relevance criteria for study inclusion. These will be very specific in WoE evaluations to assess potential endocrine disrupting properties. As observed in the substance-specific WoE evaluations reviewed in Section 3, the OECD CF can be used as a guide to identify potentially relevant study designs or endpoints investigated in publications in the open literature. This also applies to the US EPA Tier 1 and Tier 2 test battery. Using the test design and endpoints in these two frameworks as a guide does not preclude the inclusion of assays and study designs for which validated test methods are not yet available, and that are not specifically listed in the frameworks.
As highlighted by Mihaich et al. (2017) high-throughput screening results can provide additional supporting information for the MoA being evaluated. They may also be useful to identify key events that distinguish endocrine MoAs from alternative pathways that may lead to similar apical endpoints. Such data are available via the US EPA ToxCast Dashboard.
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Phase 2: Review of individual studies Adequate reliability is a prerequisite for the inclusion of study results in any hazard identification. It is accepted and recommended practice under various regulatory regimes to use numerical scores, such as the Klimisch scores (Klimisch et al., 1997) , for the assessment of reliability. More recently, additional guidance and tools have been published to make the process of reliability assessment more robust and transparent (e.g. Schneider et al., 2009; Moermond et al., 2016) . The majority of the substancespecific WoE evaluations reviewed used the JRC ToxRTool to conduct or help guide the assignment of Klimisch scores. The ToxRTool was primarily designed for the evaluation of toxicological studies; however, the general principles and guiding questions are also applicable to the evaluation of ecotoxicological studies and additional ecotoxicology specific guidance can be consulted, if required (e.g. Moermond et al., 2016) . The reliability of all studies should be documented and justified. The ToxRTool acts as a log, documenting which criteria have been met or not, thus clearly highlighting the shortcomings leading to any restrictions in reliability. Studies deemed reliable with restrictions or unreliable should be documented together with the justification for these decisions.
The data from studies considered relevant in Phase 1 and assessed as reliable in Phase 2 should then be extracted, summarised, and arranged according to the OECD CF Levels. The substancespecific WoEs reviewed in Section 3 have shown that it can be useful to arrange the positive and negative evidence for each hypothesised endocrine pathway separately. It is also useful to tabulate all other systemic effects alongside or as a parallel activity, since these can inform the evaluation of confounding effects or alternative MoA. Organisation of the data in this way can help clearly identify if sufficient information is available at the various biological levels of organisation and where any data gaps are present.
Phase 3: Data integration and assessment The data integration and assessment is the crux of the WoE evaluation for ED properties and consists of several steps, involving the evaluation of the mechanistic data and adverse effect data, and then, critically, the relationship between these data, i.e. a reasonable evidence base needs to be determined that supports that the endocrine activity determined in Level 2 or 3 assays is the basis of the adverse effect(s) observed in Level 4 and 5 studies. The WHO/ IPCS MoA e species concordance framework (Meek et al., 2014) and the AOP framework (Mihaich et al., 2016 , and references cited therein) are conceptually similar frameworks that assess the WoE for MoA analysis. Both assess the WoE that supports an investigated MoA leading to an apical effect, and both use modified Bradford Hill criteria for this purpose.
In the substance-specific WoEs reviewed above, this process of assessing a plausible endocrine MoA was begun by assessing the consistency of the results within assays/studies. If more than one study is available, are the same or similar results observed (consistency across assays/studies)? This is followed by assessing the coherence of results across different study types, i.e. is the pattern of effects observed in the various tiers of biological organisation coherent with the hypothesised MoA?
The reviewed examples highlight the advantages of presenting the evidence in tabulated, as well as in narrative, format for each endocrine pathway being investigated. Example tables of how the data can be evaluated are provided in Meek et al. (2014) and Mihaich et al. (2016) . ECHA table templates to record data for MoA analysis are also available.
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Factors that should be considered carefully during the evaluation of the data are potential confounders, such as systemic or overt toxicity, general stress, liver-specific toxicity, nutritional status or altered rate of growth, and biological stressors (infection/parasites). Clear tabular presentation of any confounding effects alongside the data relevant for the assessment of potential endocrine disrupting properties is useful to place effects relevant for the assessment of potential endocrine disruption into context. In addition, an important consideration highlighted by Meek et al. (2014) , Mihaich et al. (2016) , and Rhomberg et al. (2013) is the explicit consideration of alternate MoA which could explain the pattern of data being evaluated.
The strength of the evidence is then evaluated using modified Bradford Hill considerations (detailed in Table 3 ) according to the WHO/IPCS MoA or AOP frameworks (Meek et al., 2014; Mihaich et al., 2016) . It should be noted that the Bradford Hill considerations are not a checklist of features, which must all be fulfilled to support a particular MoA. The considerations allow a judgement to be made on how strong the evidence is to support a particular MoA.
Once it has been established that there is sufficient WoE for a hypothesised MoA, the assessments for human health and wildlife diverge. The next step for human health assessments is to evaluate whether or to which extent the MoA would operate in humans (species concordance analysis). Concordance between mammals and humans is assumed by default, and is then evaluated by systematic consideration of the key events between and within species. Reflective of the different protection goal in ecological evaluations, the assessment for wildlife includes an assessment of the relevance of the adverse effects to population stability. Population-relevant endpoints are generally considered by assessment of survival, growth, and development (including sexual development and reproduction). However, an important consideration is also what level of effect on these endpoints may impact a population (Weltje et al., 2013) . Specific guidance on this is still lacking, but is acknowledged and in development (e.g. in draft guidance on the biological relevance of adverse effects; EFSA, 2017).
Phase 4: Drawing conclusions based on inferences In an MoA or AOP framework the individual steps of Phase 3 (data integration and assessment) clearly communicate the logic and reasoning that form the basis for drawing the conclusions. In the case of assessing endocrine disrupting properties according to the WHO definition, the conclusions will either be that there are sufficient data and confidence to conclude that the definition is met (or not met), or that there are insufficient data or confidence to draw a conclusion. Uncertainties due to data gaps or the (lack of) strength of a plausible causal relationship between endocrine activity and adverse effects will have been highlighted during the data integration and assessment phase, and will directly inform the conclusions.
In conclusion, the requirement for the WoE evaluation for potential ED properties is embedded in European legislation governing PPPs and BPs. The recommendations made in this paper draw on existing, established methods and best practice frameworks, as well as an evaluation of how they have been applied in practice. The implementation of these recommendations will allow transparent and robust WoE evaluations of potential ED properties in a European hazard based regulatory context. However, good regulatory practice should not rely on hazard identification alone. Substances that are identified as endocrine disruptors should also undergo a comprehensive risk assessment. Table 3 Modified Bradford Hill considerations (Meek et al., 2014) .
Concordance of dose-response relationships between key and end events • Dose-response relationships for key events are compared with one another and with those for endpoints of concern. (Are the key events always observed at doses below or similar to those associated with toxic outcome?) Temporal association • Key events and adverse outcomes are evaluated to determine if they occur in expected order Consistency and specificity (essentiality)
• Is the incidence of the toxic effect consistent with that for the key events?
• Is the sequence of events reversible if dosing is stopped or a key event prevented? Biological plausibility • Is the pattern of effects across species/strains/systems consistent with the hypothesised MoA?
• Does the hypothesised MoA make sense based on broader knowledge?
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